查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1492645

慢性顽固性咳嗽市场：按药物类型、分销管道划分 - 全球预测 2024-2030

Chronic Refractory Cough Market by Drug Type (Amitriptyline, Gabapentin, Pregabalin), Distribution Channel (Drug Store, Hospital Pharmacies, Online Pharmacies) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

慢性顽固性咳嗽市场规模预计2023年为55.7亿美元，预计2024年将达到58.8亿美元，2030年将达到83.2亿美元，复合年增长率为5.88%。

慢性难治性咳嗽 (CRC) 市场包括解决对传统治疗超过八週没有反应的持续性咳嗽。气喘、慢性阻塞性肺病和支气管炎等慢性呼吸道疾病的增加自然会导致慢性顽固性咳嗽病例的增加。医疗基础设施的改善和对结直肠癌认识的提高正在增加寻求慢性咳嗽治疗的人数，从而扩大了市场。创新的治疗方法和医疗技术的进步带来了 CRC 的高效治疗和管理，也是市场的重要成长动力。然而，由于大肠直肠癌的症状与其他轻微疾病相似，因此经常被误诊或忽视，从而阻碍有效的治疗。目前可用的一些治疗方法具有显着的副作用，这可能会阻碍患者并挑战他们继续接受处方治疗的能力。此外，透过开发专为大肠直肠癌管理设计的新药物配方和先进治疗设备，还有巨大的成长机会。将 CRC 管理与远端医疗平台结合可以增加患有这种疾病的患者的可近性，并促进持续管理，而无需频繁去医院。

主要市场统计
基准年[2023] 55.7亿美元
预测年份 [2024] 58.8亿美元
预测年份 [2030] 83.2亿美元
复合年增长率（%） 5.88%

区域洞察

在美洲，美国和加拿大凭藉着先进的医疗基础设施和对呼吸道疾病的高度意识层级，在慢性顽固性咳嗽治疗市场中占据主要地位。美国最近的专利趋势集中在新型咳嗽药物和咳嗽管理设备上，凸显了治疗中技术整合的趋势。欧盟市场受到严格法规的指导，对有效和安全治疗的需求不断增长。欧盟消费行为的特征是偏好实证治疗方法。中东地区对包括大肠癌在内的慢性病的认识和医疗支出正在增加。中东地区对专业医疗服务和先进治疗方法的国际合作越来越感兴趣。非洲地区最近旨在改善医疗基础设施和可近性的倡议可能会增加对 CRC 管理解决方案的长期需求。在亚太地区，中国的医疗基础设施得到了快速改善，包括慢性咳嗽的治疗。日本的结直肠癌治疗通常使用政府医疗政策支持的最尖端科技和药物。由于人口老化，日本也是 CRC 管理解决方案的重要市场。在印度，不断壮大的中产阶级和不断改善的医疗设施正在为 CRC 管理创造巨大的商机。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在慢性难治性咳嗽市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检查了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对慢性顽固性咳嗽市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该行业竞争性质的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在慢性顽固性咳嗽市场中的地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性顽固性咳嗽盛行率普及
      • 政府对认识和早期诊断的支持
    • 抑制因素
      • 药品召回的潜在风险
    • 机会
      • 加强有效药物开发的研究和开发工作
      • 协作药物开发和降低医疗成本
    • 任务
      • CRC 治疗相关的副作用
  • 市场区隔分析
    • 药物类型：探索Gabapentin作为治疗神经病变相关慢性顽固性咳嗽的创新疗法
    • 通路：慢性顽固性咳嗽网路药局越来越受欢迎
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 慢性难治性咳嗽市场药物按类型

  • 阿米替林
  • Gabapentin
  • Pregabalin

第七章慢性顽固性咳嗽市场：依通路划分

  • 药局
  • 医院药房
  • 网路药房

第八章 北美和南美慢性难治性咳嗽市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区慢性顽固性咳嗽市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲慢性难治性咳嗽市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 呼吸治疗新药投资快速增加：Notion Therapeutics开发tupulcanium聚焦慢性顽固咳嗽
    • Trevi Therapeutics 与 Haduvio 开始 2a 期 RIVER 试验，推进难治性慢性咳嗽的治疗
    • GSK PLC 完成对 BELLUS Health Inc. 的收购，增强慢性难治性咳嗽治疗产品组合
  • 战略分析和建议

第12章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-9A2BA9536664

[182 Pages Report] The Chronic Refractory Cough Market size was estimated at USD 5.57 billion in 2023 and expected to reach USD 5.88 billion in 2024, at a CAGR 5.88% to reach USD 8.32 billion by 2030.

The Chronic Refractory Cough (CRC) market involves addressing a persistent cough that remains unresponsive to traditional treatments for more than eight weeks. Rising incidences of chronic respiratory conditions such as asthma, COPD, and bronchitis naturally lead to an increase in cases of chronic refractory coughs. Improved healthcare infrastructure and heightened awareness about CRC have led more individuals to seek treatment for chronic coughs, thus expanding the market. Innovative therapeutic approaches and advancements in medical technologies that offer higher efficacy in treating or managing CRC are also critical growth drivers in the market. However, CRC can often be misdiagnosed or overlooked as its symptoms may resemble those of other less severe illnesses, which can impede effective treatment. Some current treatments available have significant side effects, which might deter patients, creating challenges for continuing with their prescribed therapies. Moreover, there is a substantial opportunity for growth through the development of new pharmaceutical formulations and advanced therapeutic devices designed specifically for CRC management. Integrating CRC management with telehealth platforms can enhance accessibility for patients struggling with this condition, facilitating continuous management without frequent hospital visits.

KEY MARKET STATISTICS
Base Year [2023] USD 5.57 billion
Estimated Year [2024] USD 5.88 billion
Forecast Year [2030] USD 8.32 billion
CAGR (%) 5.88%

Regional Insights

In the Americas region, the U.S. and Canada represent a substantial market for the management of chronic refractory cough due to its advanced healthcare infrastructure and high awareness levels regarding respiratory conditions. Recent patents in the U.S. have focused on novel cough suppressant therapies and cough management devices, highlighting a trend toward technological integration in treatment. The EU market is guided by stringent regulations that drive the demand for highly effective and safe treatments. Consumer behavior in the EU is characterized by a preference for evidence-based therapies. In the Middle East, there is increasing awareness and healthcare expenditure concerning chronic diseases, including CRC. The Middle East region shows growing interest in specialized healthcare services and international collaborations for advanced treatment methods. Recent initiatives in the African region aim to improve healthcare infrastructure and accessibility, which may increase the demand for CRC management solutions in the long term. In the APAC region, China has seen rapid health infrastructure improvements, which extend to the management of chronic coughs. CRC treatment in Japan often involves cutting-edge technology and pharmaceuticals supported by government-backed healthcare policies. Japan's aging population also makes it a critical market for CRC management solutions. In India, the rising middle class and improvements in healthcare facilities are creating significant opportunities for CRC management.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Chronic Refractory Cough Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising prevalence of chronic refractory cough
      • Government support for awareness and early diagnosis
    • Market Restraints
      • Potential risk of drug recall
    • Market Opportunities
      • Increasing R&D initiatives toward effective drug development
      • Collaborative drug development and improving healthcare expenditure
    • Market Challenges
      • Side effects associated CRC treatment
  • Market Segmentation Analysis
    • Drug Type: Exploring gabapentin for innovative treatments for chronic refractory cough with neuropathic links
    • Distribution Channel: Increasing preference to online pharmacies for chronic refractory cough treatment
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Chronic Refractory Cough Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Chronic Refractory Cough Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Investment Surge in Novel Respiratory Therapeutics: Focus on Nocion Therapeutics' Development of Taplucanium for Chronic Refractory Cough

Nocion Therapeutics, based in Watertown, Massachusetts, has completed a USD 62 million Series B funding round to advance the development of their innovative drug, taplucanium. Nocion is pioneering a novel approach by targeting the nociceptors-sensory neurons that trigger pain, itching, or coughs-which are implicated in various conditions including chronic refractory cough, a difficult-to-treat condition characterized by a persistent cough without a clear underlying cause [Published On: 2024-03-04]

Trevi Therapeutics Launches Phase 2a RIVER Trial for Haduvio, Advancement in Refractory Chronic Cough Treatment

Trevi Therapeutics, Inc., a pioneering company in clinical-stage biopharmaceuticals, recently initiated the Phase 2a RIVER clinical trial to assess the efficacy of Haduvio (oral nalbuphine ER) in treating patients with refractory chronic cough (RCC). The RIVER trial, a rigorous double-blind, placebo-controlled study with a 2-period crossover design, aims to enroll approximately 60 participants who suffer from moderate to severe cough frequencies [Published On: 2023-11-02]

GSK PLC Finalizes Acquisition of BELLUS Health Inc. Health to Enhance Chronic Refractory Cough Treatment Portfolio

GSK PLC has acquired BELLUS Health Inc., integrating BELLUS Health Inc.'s promising drug candidate, camlipixant, a highly selective P2X3 antagonist into its respiratory therapy lineup. Camlipixant, now in phase III trials, targets the first line treatment of adult patients with refractory chronic cough. The transaction, endorsed by BELLUS Health Inc. shareholders to leverage GSK PLC's robust R&D, manufacturing, and commercialization capabilities to expedite the drug's market launch. [Published On: 2023-06-28]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Chronic Refractory Cough Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Chronic Refractory Cough Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare Inc., Alitair Pharmaceuticals, Amneal Pharmaceuticals Inc., Apotex Inc., AstraZeneca PLC, Aurobindo Pharma Ltd, Bausch Health, Bayer AG, Cipla Inc., Dr Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., GSK PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Mylan N.V. by Viatris Inc., NeRRe Therapeutics, Novartis AG, Pfizer Inc., Sienna Biotec, Strides Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd. by Ipca Labs, and Zydus Pharmaceuticals USA Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Refractory Cough Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Amitriptyline
    • Gabapentin
    • Pregabalin
  • Distribution Channel
    • Drug Store
    • Hospital Pharmacies
    • Online Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic refractory cough
      • 5.1.1.2. Government support for awareness and early diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of drug recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D initiatives toward effective drug development
      • 5.1.3.2. Collaborative drug development and improving healthcare expenditure
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated CRC treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Exploring gabapentin for innovative treatments for chronic refractory cough with neuropathic links
    • 5.2.2. Distribution Channel: Increasing preference to online pharmacies for chronic refractory cough treatment
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Chronic Refractory Cough Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Amitriptyline
  • 6.3. Gabapentin
  • 6.4. Pregabalin

7. Chronic Refractory Cough Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Drug Store
  • 7.3. Hospital Pharmacies
  • 7.4. Online Pharmacies

8. Americas Chronic Refractory Cough Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Chronic Refractory Cough Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Chronic Refractory Cough Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Investment Surge in Novel Respiratory Therapeutics: Focus on Nocion Therapeutics' Development of Taplucanium for Chronic Refractory Cough
    • 11.3.2. Trevi Therapeutics Launches Phase 2a RIVER Trial for Haduvio, Advancement in Refractory Chronic Cough Treatment
    • 11.3.3. GSK PLC Finalizes Acquisition of BELLUS Health Inc. Health to Enhance Chronic Refractory Cough Treatment Portfolio
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CHRONIC REFRACTORY COUGH MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC REFRACTORY COUGH MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CHRONIC REFRACTORY COUGH MARKET DYNAMICS
  • FIGURE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC REFRACTORY COUGH MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY GABAPENTIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY PREGABALIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG STORE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 25. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 26. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 27. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 28. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 36. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 37. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 48. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 50. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 60. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 61. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 68. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 69. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 111. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 118. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 119. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2023